Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen-Reference-Cited by-同舟云学术

Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen

Published:2019-08-01 Issue:10 Volume:33 Page:1583-1593
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Rizzardini Giuliano,Gori Andrea,Miralles Celia,Olalla Julián,Molina Jean-Michel,Raffi François,Kumar Princy,Antinori Andrea,Ramgopal Moti,Stellbrink Hans-Jürgen,Das Moupali,Chu Hoa,Ram Renee,Garner Will,Shao Yongwu,Chuck Susan K.,Piontkowsky David,Haubrich Richard H.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference55 articles.

1. Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence;Orkin;HIV Med,2018

2. Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: Week 144 results;Arribas;J Acquir Immune Defic Syndr,2017

3. Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment;DeJesus;AIDS Res Hum Retroviruses,2018

4. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study;Moyle;Antivir Ther,2013

5. Use of abacavir and risk of cardiovascular disease among HIV-infected individuals;Marcus;J Acquir Immune Defic Syndr,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors associated with patient satisfaction with antiretroviral therapy in Japan: A cross-sectional, multicenter study;Journal of Infection and Chemotherapy;2024-02

2. Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study;AIDS Research and Therapy;2023-01-03

3. Advantages of switching to elvitegravir/cobicistat/emtricitabine/tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome;Chinese Medical Journal;2022-12-28

4. Using a single tablet regimen of darunavir, cobicistat, emcitrabine, and tenofovir alafenamide in virally suppressed HIV-1 patients is an adequate treatment option for controlling HIV;Clinical Research In Practice: The Journal of Team Hippocrates;2021-10-13

5. Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation;JAIDS Journal of Acquired Immune Deficiency Syndromes;2020-12-10